COPD Mortality Risk: Demographic Disparities in Hospitalized Patients
Thirty-day mortality outcomes for patients hospitalized for acute COPD exacerbations in the US appear to vary based on their demographics. Males are at elevated...
Inhaled Dry Powder Treprostinil Shows Safety and Efficacy in PH-ILD
In patients with pulmonary hypertension-interstitial lung disease (PH-ILD), treatment with LIQ861 (YUTREPIA™, Liquidia Corporation), a novel inhaled dry powder formulation of treprostinil, appears to...
GLP-1 Receptor Agonists May Increase Survival in Patients With T2DM and OSA
Glucagon-like peptide-1 (GLP-1) receptor agonists appear to reduce mortality in people with type 2 diabetes (T2DM). A new study of nearly 1.8 million patients...
GLP-1 Receptor Agonists Show Promise for Right Heart Failure in PAH
Although patients with pulmonary arterial hypertension (PAH) treated with glucagon-like peptide-1 (GLP-1) receptor agonists and SGLT2 inhibitors have comparable mortality rates, GLP-1 receptor agonists...